Galectins are a family of proteins that have become a promising source of cancer research in recent years.

A representative thereof is galectin-1.

It sits on the surface of all human cells; on tumour cells, however, it occurs in enormous quantities.

This makes it an interesting target for diagnostics and therapy.

"Among other things, it is known that galectin-1 hides the tumour cells from the immune system," explains Professor Jürgen Seibel of the Institute of Organic Chemistry at the Julius-Maximilians-Universität (JMU) Würzburg in Bavaria, Germany. Recent studies have shown that when Galectin-1 is blocked, the immune system can recognize the tumour and attack it with T cells.

No wonder, therefore, that galectin-1 has become a major focus of research.

Seibel and his colleague Dr. Clemens Grimm is interested in a very specific section of this protein, the so-called carbohydrate recognition domain.

They have now designed a complex sugar molecule that fits perfectly into this domain, as the scientists report in journal ChemBioChem.

"We have equipped the sugar molecule with a docking site, for example, to connect it with a fluorescent dye or a drug," says Seibel. In addition, the scientists have described the binding of their molecule to galectin-1 with high-resolution X-ray structure analyses.

"Our findings can serve the development of high-affinity ligands of the protein Galectin-1 and thus of new drugs," said Clemens Grimm.

Now the JMU scientists are working on a rapid test for the detection of galectin-1.

It is designed to enable early detection of tumours such as neuroblastoma.

For the future, Seibel's team would like to expand the sugar molecules into a kind of shuttle system that allows pharmaceutical agents to be transported directly to the tumours.

Source: University of Würzburg